BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20835521)

  • 1. Methemoglobinemia and dapsone levels in patients with leprosy.
    Vieira JL; Riveira JG; Martins Ade N; Silva JP; Salgado CG
    Braz J Infect Dis; 2010; 14(3):319-21. PubMed ID: 20835521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.
    Penna GO; Bührer-Sékula S; Kerr LRS; Stefani MMA; Rodrigues LC; de Araújo MG; Ramos AMC; de Andrade ARC; Costa MB; Rosa PS; Gonçalves HS; Cruz R; Barreto ML; Pontes MAA; Penna MLF
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005725. PubMed ID: 28704363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects.
    Gonçalves Hde S; Pontes MA; Bührer-Sékula S; Cruz R; Almeida PC; Moraes ME; Penna GO
    Mem Inst Oswaldo Cruz; 2012 Dec; 107 Suppl 1():74-8. PubMed ID: 23283457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT.
    Queiroz RH; Melchior Júnior E; de Souza AM; Gouveia E; Barbosa JC; de Carvalho D
    Pharm Acta Helv; 1997 Sep; 72(4):209-13. PubMed ID: 9372643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapsone and body mass index in subjects with multibacillary leprosy.
    Moura FM; Dias RM; Araujo EC; Brasil LM; Ferreira MV; Vieira JL
    Ther Drug Monit; 2014 Apr; 36(2):261-3. PubMed ID: 24232126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapsone syndrome with acute renal failure during leprosy treatment: case report.
    Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Fontes CJ
    Braz J Infect Dis; 2005 Feb; 9(1):84-6. PubMed ID: 15947852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pilot study: Clarithromycin efficacy in multibacillary leprosy therapy.
    Gunawan H; Sasmojo M; Putri HE; Avriyanti E; Hindritiani R; Suwarsa O
    Int J Mycobacteriol; 2018; 7(2):152-155. PubMed ID: 29900892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
    Deps P; Guerra P; Nasser S; Simon M
    Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapsone hypersensitivity syndrome in an adolescent during treatment during of leprosy.
    Bucaretchi F; Vicente DC; Pereira RM; Tresoldi AT
    Rev Inst Med Trop Sao Paulo; 2004; 46(6):331-4. PubMed ID: 15654479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
    Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
    An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiologic mechanisms, diagnosis, and management of dapsone-induced methemoglobinemia.
    Ashurst JV; Wasson MN; Hauger W; Fritz WT
    J Am Osteopath Assoc; 2010 Jan; 110(1):16-20. PubMed ID: 20093649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Report: Borderline Lepromatous Leprosy Therapy Complicated by Type 1 Leprosy Reaction and Adverse Reactions with Dapsone and Clofazimine.
    Matono T; Suzuki S; Mori S; Ato M
    Am J Trop Med Hyg; 2024 Mar; 110(3):483-486. PubMed ID: 38266303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined chemotherapy of multibacillary leprosy of 6 months' duration.
    Onsun N; Saylan T; Pattyn SR
    Lepr Rev; 1986; 57 Suppl 3():124-6. PubMed ID: 3573952
    [No Abstract]   [Full Text] [Related]  

  • 15. Case Report: A Case of Type 1 Leprosy Reaction and Dapsone Hypersensitivity Syndrome Complicating the Clinical Course of Multibacillary Leprosy.
    Craig J; MacRae C; Melvin RG; Boggild AK
    Am J Trop Med Hyg; 2019 May; 100(5):1145-1148. PubMed ID: 30915953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapsone-induced methemoglobinemia in leprosy patients.
    Kaur I; Mehta M; Agnihotri N; Dogra S; Ganguly NK
    Int J Lepr Other Mycobact Dis; 2001 Sep; 69(3):247-9. PubMed ID: 11875770
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined regimens of one year duration in the treatment of multibacillary leprosy--I. Combined regimens with rifampicin administered during one year.
    Pattyn SR; Bourland J; Grillone S; Groenen G; Ghys P
    Lepr Rev; 1989 Jun; 60(2):109-17. PubMed ID: 2671559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The recognition, physiology, and treatment of medication-induced methemoglobinemia: a case report.
    Turner MD; Karlis V; Glickman RS
    Anesth Prog; 2007; 54(3):115-7. PubMed ID: 17900210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical oxidative stress during leprosy multidrug therapy: impact of dapsone oxidation.
    Schalcher TR; Borges RS; Coleman MD; Batista Júnior J; Salgado CG; Vieira JL; Romão PR; Oliveira FR; Monteiro MC
    PLoS One; 2014; 9(1):e85712. PubMed ID: 24465659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and hematological side effects of clofazimine in leprosy patients.
    Costa Queiroz RH; de Souza AM; Sampaio SV; Melchior E
    Pharmacol Res; 2002 Aug; 46(2):191-4. PubMed ID: 12220960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.